ReviewOncoTargets and therapy2018
TIM-3, a promising target for cancer immunotherapy.
Yayi He et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
137 papers cite itlatest 60 shown
this papercites it
ReviewOncoTargets and therapy2018
Yayi He et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.